Treatment abandonment in childhood acute lymphoblastic leukaemia in China: a retrospective cohort study of the Chinese Children's Cancer Group
- PMID: 30705079
- DOI: 10.1136/archdischild-2018-316181
Treatment abandonment in childhood acute lymphoblastic leukaemia in China: a retrospective cohort study of the Chinese Children's Cancer Group
Abstract
Objectives: Before 2003, most children with acute lymphoblastic leukaemia (ALL) abandoned treatment, with only approximately 30% treated in China. With the development of national insurance for underprivileged patients, we assessed the current frequency and causes of treatment abandonment among patients with ALL who were enrolled in the Chinese Children's Cancer Group ALL protocol between 2015 and 2016.
Methods: Demographic, clinical and laboratory data on patients who abandoned treatment, as well as economic and sociocultural data of their families were collected and analysed. General health-related statistics were retrieved from publicly accessible databanks maintained by the Chinese government.
Results: At a median follow-up of 119 weeks, 83 (3.1%, 95% CI 2.5% to 3.8%) of the 2641 patients abandoned treatment. Factors independently associated with abandonment included standard/high-risk ALL (OR 2.62, 95% CI 1.43 to 4.77), presence of minimal residual disease at the end of remission induction (OR 3.57, 95% CI 1.90 to 6.74) and low-income economic region (OR 3.7, 95% CI 1.89 to 7.05). According to the family members, economic constraints (50.6%, p=0.0001) were the main reason for treatment abandonment, followed by the belief of incurability, severe side effects and concern over late complications.
Conclusions: The rate of ALL treatment abandonment has been greatly reduced in China. Standard/high-risk ALL, residence in a low-income region and economic difficulties were associated with treatment abandonment.
Clinical trial registration number: ChiCTR-IPR-14005706, pre-results.
Keywords: economic difficulties; paediatric acute lymphoblastic leukaemia; treatment abandonment.
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Similar articles
-
Prevalence, predictors, causes of treatment refusal and abandonment in children with acute lymphoblastic leukaemia over 18 years in North India. Treatment phase affecting factors: A step towards better focussed counselling.Cancer Epidemiol. 2018 Dec;57:53-59. doi: 10.1016/j.canep.2018.07.011. Epub 2018 Oct 11. Cancer Epidemiol. 2018. PMID: 30316108
-
A report about treatment refusal and abandonment in children with acute lymphoblastic leukemia in China, 1997-2007.Leuk Res. 2011 Dec;35(12):1628-31. doi: 10.1016/j.leukres.2011.07.004. Epub 2011 Jul 29. Leuk Res. 2011. PMID: 21802727
-
Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.Lancet Oncol. 2015 Apr;16(4):465-74. doi: 10.1016/S1470-2045(15)70082-3. Epub 2015 Mar 20. Lancet Oncol. 2015. PMID: 25800893 Free PMC article. Clinical Trial.
-
Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.J Pediatr Hematol Oncol. 2001 Dec;23(9):591-7. doi: 10.1097/00043426-200112000-00008. J Pediatr Hematol Oncol. 2001. PMID: 11902303 Review.
-
Advances in therapy for childhood non-B-lymphoblastic leukaemia.Baillieres Clin Haematol. 1994 Jun;7(2):273-98. doi: 10.1016/s0950-3536(05)80203-3. Baillieres Clin Haematol. 1994. PMID: 7803902 Review.
Cited by
-
High-Dose Methotrexate-Induced Idiopathic Intracranial Hypertension in Infant Acute Lymphoblastic Leukemia.Front Pharmacol. 2020 Jun 17;11:839. doi: 10.3389/fphar.2020.00839. eCollection 2020. Front Pharmacol. 2020. PMID: 32625086 Free PMC article.
-
Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.JAMA Oncol. 2020 Mar 1;6(3):358-366. doi: 10.1001/jamaoncol.2019.5868. JAMA Oncol. 2020. PMID: 31944221 Free PMC article. Clinical Trial.
-
[Prognostic significance and risk factors of minimal residual disease ≥1% on 19th day of induction chemotherapy in children with acute lymphoblastic leukemia].Nan Fang Yi Ke Da Xue Xue Bao. 2020 Feb 29;40(2):255-261. doi: 10.12122/j.issn.1673-4254.2020.02.18. Nan Fang Yi Ke Da Xue Xue Bao. 2020. PMID: 32376526 Free PMC article. Chinese.
-
Characteristics in gut microbiome is associated with chemotherapy-induced pneumonia in pediatric acute lymphoblastic leukemia.BMC Cancer. 2021 Nov 8;21(1):1190. doi: 10.1186/s12885-021-08917-y. BMC Cancer. 2021. PMID: 34749705 Free PMC article.
-
Cytogenetic Characteristics of Childhood Acute Lymphoblastic Leukemia: A Study of 1541 Chinese Patients Newly Diagnosed between 2001 and 2014.Curr Med Sci. 2022 Feb;42(1):201-209. doi: 10.1007/s11596-021-2477-0. Epub 2021 Dec 6. Curr Med Sci. 2022. PMID: 34874488
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources